MODULATORS OF LXR
Granted: December 30, 2010
Application Number:
20100331295
Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
Marks as modifiers of the p53 pathway and methods of use
Granted: December 23, 2010
Application Number:
20100325743
Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
Inhibitors of mTOR and Methods of Making and Using
Granted: December 2, 2010
Application Number:
20100305093
The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
Granted: November 25, 2010
Application Number:
20100298290
The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
HADHs as Modifiers of the p21 Pathway and Methods of Use
Granted: October 28, 2010
Application Number:
20100275275
Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
Modulators of S1P and Methods of Making And Using
Granted: September 30, 2010
Application Number:
20100249071
The invention is directed to Compounds of Formula I: as well as methods of making and using the compounds.
Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases
Granted: September 30, 2010
Application Number:
20100249096
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.
METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA
Granted: August 19, 2010
Application Number:
20100209420
The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments. (Formula I)
GALK1S AS MODIFIERS OF THE PTEN/AKT PATHWAY AND METHODS OF USE
Granted: July 22, 2010
Application Number:
20100183583
Human GALK1 genes are identified as modulators of the PTEN/AKT pathway, and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT, comprising screening for agents that modulate the activity of GALK1 are provided.
Azepinoindole Derivatives As Pharmaceutical Agents
Granted: July 8, 2010
Application Number:
20100173824
Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
SCDs As Modifiers of the p53 Pathway and Methods of Use
Granted: June 24, 2010
Application Number:
20100159470
Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
S1P1 Agonists and Methods of Making And Using
Granted: June 24, 2010
Application Number:
20100160369
The invention is directed to Compounds of Formula I: as well as methods of making and using the compounds.
PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER
Granted: June 17, 2010
Application Number:
20100150827
The invention is directed to a Compound of Formula I, II, or III. The invention provides compounds that inhibit, regulate, and/or modulate PI3K that are useful in the treatment of hyperproliferatives diseases, such as cancer.
Pyrimidinones as Casein Kinase II (CK2) Modulators
Granted: June 10, 2010
Application Number:
20100144770
A compound having Formula I: or a pharmaceutically acceptable salt thereof, wherein X, R, R and R are as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof. The compounds of Formula I are inhibitors of Casein kinase II (CK2) pathways.
6-Phenylpyrimidinones as PIM Modulators
Granted: June 3, 2010
Application Number:
20100135954
A compound having Formula I or II (Formula I) or (Formula II), or a pharmaceutically acceptable salt thereof, wherein X, Z, R1, R2, R11 and R12 are as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof.
JAK-2 Modulators and Methods of Use
Granted: June 3, 2010
Application Number:
20100136136
This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that…
CDC6S AS MODIFIERS OF THE PTEN/AKT PATHWAY AND METHODS OF USE
Granted: May 13, 2010
Application Number:
20100122354
Human CDC6 genes are identified as modulators of the PTEN/AKT pathway, and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT, comprising screening for agents that modulate the activity of CDC6 are provided.
11 BETA-HSD1 MODULATORS
Granted: April 29, 2010
Application Number:
20100105675
A compound according to Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R11, L1 and X are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
PYRIDOPYRIMIDINONE INHIBITORS OF PI3K-ALPHA and mTOR
Granted: April 8, 2010
Application Number:
20100087456
The invention is directed to Compounds of Formula I: optionally as a single stereoisomer or mixture of stereoisomers thereof, and additionally optionally as a pharmaceutically acceptable salt thereof; as well as methods of making and using the compounds.
Methods of Using PI3K and MEK Modulators
Granted: March 25, 2010
Application Number:
20100075947
The invention provides methods of treating cancer with a combination of compounds which inhibit kinases, more specifically MEK and PI3K.
